Clinical Trial Update: BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects

View source ↗

Summary

This clinical trial update reports on a study comparing once-daily lopinavir/ritonavir to the standard twice-daily regimen in HIV-infected subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Kaletra (lopinavir)

Snippet

Sponsor: Bellos, Nicholaos C., M.D. | Conditions: HIV Infections | Status: UNKNOWN